ALK and neuroblastoma: We, therefore, set out to determine ALK alteration frequencies and associations with clinical variables in a large cohort of diagnostic and relapsed neuroblastomas that were obtained from patients treated within successive trials and registries of the Gesellschaft für Pädiatrische Onkologie (GPOH).